6
Oct
2026
Rezon Bio
About Rezon Bio
Certifications
-
FDA -
GMP -
ISO
Categories
Meet us at
-
CPHI Milan 2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026stand 12J42
-
Country/Region:Poland
-
Founded:2012
-
On CPHI since:2025
-
Certificates:4
-
Employees:1000 - 4999
Company types
Primary activities
Contact info
-
-
-
Trzy Lipy 3 Building A, Gdansk Science & Technology Park, 80-172, Gdansk, Poland
Products from Rezon Bio (4)
-
Product End-to-end services
Mirrored equipment and capabilities, processes and analytical approaches enable seamless and rapid scale up and tech transfer projects to serve clients worldwide. -
Product Biologics CDMO Services
End 2 end, from gene to commercial CDMO services for biologics -
Product Economics first process development
Process development for NBEs and biosimilars -
Product Tech Transfer & Scale-up Biologics
Fast and price competitive tech transfers and scale up services
Rezon Bio Resources (3)
-
News How to Choose a Biologics CDMO?
Knowing how to choose a biologics CDMO matters as it’s one of the most important strategic decisions any biotech or pharma company will make. The right partner can accelerate development, reduce technical and regulatory risk, and support a smoother path to commercialization. The wrong one can introduce delays, increase costs, and create challenges that are difficult to resolve later in the program.
-
Brochure Rezon Bio Company Overview | End-to-end Biologics CDMO
Rezon Bio is a science-driven, price-competitive contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of mammalian biologics. Headquartered in Poland, Rezon Bio offers integrated solutions spanning cell line development, commercial drug substance manufacturing, and drug product development. The company operates with state-of-the-art facilities, world-class teams, and a proven track record of regulatory and commercial success. -
News Rezon Bio launches as a European biologics CDMO combining cost efficiency and digital innovation.
New brand with proven track record – EMA and FDA-audited mirrored-capability sites in Poland provide an accelerated path from development to commercialization.